Bio-Techne Corporation

NASDAQ:TECH

Biotechnology

Healthcare
$72.75 -1.84%

-$1.03 today

Market cap
$11.43B
Beta
1.36
P/E (TTM)
78.3
EPS (TTM)
$0.70
Dividend yield
0.58%
52W Low $43.20High $72.16

Volume 2.63M

Average 2.66M

TECH EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Bio-Techne CorporationNASDAQ: TECH

EBITDA · Q1 FY2027 · quarter ended Sep 2026

EBITDA dips below year-ago levels

Q1 FY2027 EBITDA of $60.59M fell 19.5% year over year, behind the +48.3% change in trailing-twelve-month EBITDA. Sequentially, it fell 34.1% from the prior quarter. Over 3 fiscal years it compounded at -9.1% a year.

Context

  • EBITDA amounted to 28.3% of revenue in FY2026, up 10.5 pp from a year earlier.
  • EBITDA increased in 1 of the last 3 fiscal years.

What to watch

Whether EBITDA reaches the consensus estimate from 7 analysts of $487.21M (+41.9%) for the fiscal year ending Jun 2027, a slowdown from the +58.4% reported in FY2026.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
$60.59M-34.1% QoQ
Last fiscal yearJun 2026
$343.44M+58.4% YoY
LTMSep 2026
$328.77M+48.3% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-19.5%+45.9%+65.4 pp
1 year+58.4%+41.9%-16.5 pp
3-year CAGR-9.1%+16.4%+25.5 pp
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2026
343.44M USD
Year-over-year change
+58.4%
4-year CAGR
-4.6%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How TECH compares with its peers on the latest reported figures

  • TECH's LTM Sep 2026 EBITDA of $328.77M is the 7th highest of the 11 companies compared; the peer median is $609.04M.
  • Its year-over-year change of +48.3% is the 2nd highest of 10, against a peer median of -0.8%.
  • EBITDA amounts to 26.8% of revenue for TECH, versus a peer median of 27.0%.
TECH Competitors Peer median
EBITDA for TECH and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TMOThermo Fisher Scientific Inc.LTM Sep 2026$11.24B -0.8%-1.3%23.7%
DHRDanaher CorporationLTM Sep 2026$7.09B +3.2%-9.9%27.7%
AAgilent Technologies, Inc.LTM Jul 2026$2.04B +13.2%-1.2%27.6%
RVTYRevvity, Inc.LTM Jul 2026$767M -6.7%-13.5%26.3%
QGENQiagen N.V.LTM Jun 2026$703.39M -1.6%-2.7%33.5%
BIOBio-Rad Laboratories, Inc.LTM Jun 2026$514.7M -22.7%—19.9%
TECHBio-Techne CorporationLTM Sep 2026$328.77M +48.3%-9.1%26.8%
BRKRBruker CorporationLTM Jun 2026$247.7M -38.6%-16.4%7.1%
TXG10x Genomics, Inc.LTM Sep 2026$37.56M +221.9%—6.1%
ALMRAlamar Biosciences, Inc.FY2025-$24.89M ——33.5%
SEERSeer, Inc.LTM Mar 2026-$64.35M +18.9%—427.9%
Peer median (excluding TECH) $609.04M-0.8%-6.3%27.0%

Competitors are the stored peer set for TECH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Jun 2022
FY2023
Jun 2023
FY2024
Jun 2024
FY2025
Jun 2025
FY2026
Jun 2026
Revenue1.11B1.14B1.16B1.22B1.22B
Cost of Revenue349.1M366.89M389.34M429.36M415.97M
Gross Profit756.5M769.82M769.73M790.27M799.07M
Gross Margin68.4%67.7%66.4%64.8%65.8%
Research & Development87.14M92.49M96.66M99.5M94.77M
Selling, General & Admin339M352.44M393.32M415.1M452.42M
Operating Expenses459.91M470.87M563.04M688.02M547.18M
Depreciation & Amortization101.07M107.24M111.71M109.9M97.36M
EBITDA413.76M457.11M313.14M216.88M343.44M
EBITDA Margin37.4%40.2%27.0%17.8%28.3%
Operating Income296.59M298.94M206.69M102.26M251.89M
Operating Margin26.8%26.3%17.8%8.4%20.7%
Interest Income794K3.41M3.32M3.89M0
Interest Expense11.31M11.22M15.74M8.51M5.41M
Other Income / Expenses4.8M39.72M(21M)(3.79M)(11.21M)
Income Before Tax301.39M338.66M185.69M98.46M240.68M
Pre-Tax Margin27.3%29.8%16.0%8.1%19.8%
Income Tax Expense38.29M53.22M17.58M25.06M58.82M
Net Income272.05M285.26M168.11M73.4M181.86M
Net Margin24.6%25.1%14.5%6.0%15.0%
EPS (Basic)1.731.811.070.471.17
EPS (Diluted)1.661.761.050.461.16
Weighted Avg Shares156.88M157.18M157.71M157.52M155.96M
Weighted Avg Shares (Diluted)164.12M161.86M160.77M159.72M157.01M

Bio-Techne Corporation

NASDAQ:TECH

Intrinsic Alpha fair value

Locked

Current Price

$72.75

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.